Effects of treatment with etanercept versus methotrexate on sleep quality, fatigue and selected immune parameters in patients with active rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 34, Issue 5, 2016, Pages 848-856

  Detert, Jacqueline ^a   Dziurla, René ^a,b   Hoff, Paula ^a,b   Gaber, Timo ^a,b   Klaus, Pascal ^a   Bastian, Hans ^a   Braun, Tanja ^a   Schellmann, Saskia ^a,b   Penzel, Thomas ^a   Fietze, Ingo ^a   Loeschmann, Peter Andreas ^c   Jaehnig, Peter ^d   Straub, Rainer H ^e   Burmester, Gerd R ^a   Buttgereit, Frank ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

^c PFIZER INC   (United States)

^d Pj statistics   (Germany)

^e UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

Endocrinology; Fatique; Immune response; Interleukin; Rheumatoid arthritis; Sleep quality; Treatment with etanercept versus methotrexate

Indexed keywords

C REACTIVE PROTEIN; ESTRADIOL; ETANERCEPT; INTERLEUKIN 17; INTERLEUKIN 4; METHOTREXATE; NEUROPEPTIDE Y; ANTIRHEUMATIC AGENT;

ADULT; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; DAS28; DISEASE ACTIVITY; DISEASE DURATION; DRUG EFFICACY; DRUG RESPONSE; ESTRADIOL BLOOD LEVEL; FATIGUE; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; HUMORAL IMMUNITY; MALE; POLYSOMNOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; SHORT FORM 36; SLEEP QUALITY; SLEEP STAGE; SLEEP TIME; TREATMENT OUTCOME; ADOLESCENT; AGED; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; COMPLICATION; DISABILITY; DRUG EFFECTS; IMMUNOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; PATIENT-REPORTED OUTCOME; PILOT STUDY; PREDICTIVE VALUE; QUESTIONNAIRE; REMISSION; SLEEP; SLEEP WAKE DISORDERS; TIME FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISABILITY EVALUATION; DRUG THERAPY, COMBINATION; ETANERCEPT; FATIGUE; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PATIENT REPORTED OUTCOME MEASURES; PILOT PROJECTS; POLYSOMNOGRAPHY; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; REMISSION INDUCTION; SLEEP; SLEEP WAKE DISORDERS; SURVEYS AND QUESTIONNAIRES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84988422274     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. BUTTGEREIT F, DOERING G, SCHAEFFLER A et al.: Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet 2008: 371: 205-14.
2. BUTTGEREIT F, MEHTA D, KIRWAN J et al.: Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). Ann Rheum Dis 2013: 72: 204-10.
3. KRUEGER JM, OBáL FJ, FANG J, KUBOTA T, TAISHI P: The role of cytokines in physiological sleep regulation. Ann N Y Acad Sci 2001: 933: 211-21.
4. CAPPUCCIO FP, D'ELIA L, STRAZZULLO P, MILLER MA: Sleep duration and all-cause mortality: a systematic review and metaanalysis of prospective studies. Sleep 2010: 33: 585-92.
5. CHHANGANI BS, ROEHRS TA, HARRIS EJ et al.: Pain sensitivity in sleepy pain-free normals. Sleep 2009: 32: 1011-7.
6. MOLDOFSKY H: Rheumatic manifestations of sleep disorders. Curr Opin Rheumatol 2010: 22: 59-63.
7. LØPPENTHIN K, ESBENSEN BA, JENNUM P et al.: Sleep quality and correlates of poor sleep in patients with rheumatoid arthritis. Clinical rheumatology 2015.
8. WOLFE F, HAWLEY DJ, WILSON K: The prevalence and meaning of fatigue in rheumatic disease. J Rheumatol 1996: 23: 1407-17.
9. MAHOWALD MW, MAHOWALD ML, BUNDLIE SR, YTTERBERG SR: Sleep fragmentation in rheumatoid arthritis. Arthritis Rheum 1989: 32: 974-83.
10. DREWES AM, SVENDSEN L, TAAGHOLT SJ, BJERREGÅRD K, NIELSEN KD, HANSEN B: Sleep in rheumatoid arthritis: a comparison with healthy subjects and studies of sleep/ wake interactions. Br J Rheumatol 1998: 37: 71-81.
11. TAYLOR-GJEVRE RM, GJEVRE JA, NAIR BV, SKOMRO RP, LIM HJ: Improved Sleep efficiency after anti-tumor necrosis factor a therapy in rheumatoid arthritis patients. Ther Adv Musculoskelet Dis 2011: 3: 227-33.
12. LUYSTER FS, CHASENS ER, WASKO, MARY CHESTER M, DUNBAR-JACOB J: Sleep quality and functional disability in patients with rheumatoid arthritis. J Clin Sleep Med 2011: 7: 49-55.
13. NICASSIO PM, ORMSETH SR, KAY M et al.: The contribution of pain and depression to self-reported sleep disturbance in patients with rheumatoid arthritis. Pain 2012: 153: 107-12.
14. ABAD VC, SARINAS, PRISCILLA SA, GUILLEMINAULT C: Sleep and rheumatologic disorders. Sleep Med Rev 2008: 12: 211-28.
15. WOLFE F, MICHAUD K, LI T: Sleep disturbance in patients with rheumatoid arthritis: evaluation by medical outcomes study and visual analog sleep scales. J Rheumatol 2006: 33: 1942-51.
16. LAUTENBACHER S, KUNDERMANN B, KRIEG J: Sleep deprivation and pain perception. Sleep Med Rev 2006: 10: 357-69.
17. OKIFUJI A, HARE BD: Do sleep disorders contribute to pain sensitivity? Current rheumatology reports 2011: 13: 528-34.
18. BUTTGEREIT F, SMOLEN JS, COOGAN AN, CAJOCHEN C: Clocking in: chronobiology in rheumatoid arthritis. Nature reviews. Rheumatology 2015.
19. VGONTZAS AN, ZOUMAKIS E, LIN H, BIXLER EO, TRAKADA G, CHROUSOS GP: Marked decrease in sleepiness in patients with sleep apnea by etanercept, a tumor necrosis factoralpha antagonist. J Clin Endocrinol Metab 2004: 89: 4409-13.
20. THAçI D, GALIMBERTI R, AMAYA-GUERRA M et al.: Improvement in aspects of sleep with etanercept and optional adjunctive topical therapy in patients with moderate-tosevere psoriasis: results from the PRISTINE trial. J Eur Acad Dermatol Venereol 2014: 28: 900-6.
21. SMOLEN JS, LANDEWé R, BREEDVELD FC et al.: EULAR recommendations for the management of rheumatoid arthritis with syn thetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2013.
22. ARNETT FC, EDWORTHY SM, BLOCH DA et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988: 31: 315-24.
23. PREVOO ML, van 't HOF MA, KUPER HH, van LEEUWEN MA, van de PUTTE LB, van RIEL PL: Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995: 38: 44-8.
24. RUPP I, BOSHUIZEN HC, JACOBI CE, DINANT HJ, van den BOS, GEERTRUDIS A M: Impact of fatigue on health-related quality of life in rheumatoid arthritis. Arthritis Rheum 2004: 51: 578-85.
25. FRIES JF, SPITZ P, KRAINES RG, HOLMAN HR: Measurement of patient outcome in arthritis. Arthritis Rheum 1980: 23: 137-45.
26. WARE JE, SHERBOURNE CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992: 30: 473-83.
27. WARE JE, KOSINSKI M, BAYLISS MS, McHORNEY CA, ROGERS WH, RACZEK A: Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. Med Care 1995: 33: AS264-79.
28. RECHTSCHAFFEN A, KALES A: A manual of standardized terminology, techniques and scoring system for sleep stages of human subjects. Bethesda, Md: U.S. Dept. of Health, Education, and Welfare, 1968.
29. IBER C: The AASM manual for the scoring of sleep and associated events: Rules, terminology and technical specifications. 1st. ed. Westchester Ill: American Academy of Sleep Medicine, 2007.
30. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force. Sleep 1999: 22: 667-89.
31. Recording and scoring leg movements. The Atlas Task Force. Sleep 1993: 16: 748-59.
32. HäRLE P, SARZI-PUTTINI P, CUTOLO M, STRAUB RH: No change of serum levels of leptin and adiponectin during anti-tumour necrosis factor antibody treatment with adalimumab in patients with rheumatoid arthritis. Ann Rheum Dis 2006: 65: 970-1.
33. OHAYON MM, CARSKADON MA, GUILLEMINAULT C, VITIELLO MV: Meta-analysis of quantitative sleep parameters from childhood to old age in healthy individuals: developing normative sleep values across the human lifespan. Sleep 2004: 27: 1255-73.
34. BULLINGER M, CACHOVAN M, CREUTZIG A et al.: Entwicklung eines krankheitsspezifischen Instruments zur Erfassung der Lebensqualität von Patienten mit arterieller Verschlusskrankheit (PAVK-86 Fragebogen. VASA 1996: 25: 32-40.
35. SCHWARZ R, KRAUSS O, HINZ A: Fatigue in the general population. Onkologie 2003: 26: 140-4.
36. KRISHNAN E, SOKKA T, HäKKINEN A, HUBERT H, HANNONEN P: Normative values for the Health Assessment Questionnaire disability index: benchmarking disability in the general population. Arthritis Rheum 2004: 50: 953-60.
37. GOSSEC L, STEINBERG G, ROUANET S, COMBE B: Fatigue in rheumatoid arthritis: quantitative findings on the efficacy of tocilizumab and on factors associated with fatigue. The French multicentre prospective PEPS Study. Clin Exp Rheumatol 2015; 33: 664-70.
38. LEE YC, LU B, EDWARDS RR et al.: The role of sleep problems in central pain processing in rheumatoid arthritis. Arthritis Rheum 2013: 65: 59-68.
39. GJEVRE JA, TAYLOR-GJEVRE RM, NAIR BV, LIM HJ: Do sleepy rheumatoid arthritis patients have a sleep disorder? Musculoskeletal Care 2012: 10: 187-95.
40. ROEHRS T, DIEDERICHS C, GILLIS M et al.: Nocturnal sleep, daytime sleepiness and fatigue in fibromyalgia patients compared to rheumatoid arthritis patients and healthy controls: a preliminary study. Sleep Med 2013: 14: 109-15.
41. CLARKE LL, WILSON S, KIRWAN JR: Using actigraphy to measure sleep patterns in rheumatoid arthritis: a pilot study in patients taking night-time prednisone. Musculoskeletal Care 2013: 11: 179-85.
42. CAMPBELL, RCJ, BATLEY M, HAMMOND A, IBRAHIM F, KINGSLEY G, SCOTT DL: The impact of disease activity, pain, disability and treatments on fatigue in established rheumatoid arthritis. Clin Rheumatol 2012: 31: 717-22.
43. van HOOGMOED D, FRANSEN J, REPPINGWUTS H, SPEE L, BLEIJENBERG G, van RIEL, PLCM: The effect of anti-TNF-a vs. DMARDs on fatigue in rheumatoid arthritis patients. Scand J Rheumatol 2013: 42: 15-9.
44. FRAGIADAKI K, TEKTONIDOU MG, KONSTA M, CHROUSOS GP, SFIKAKIS PP: Sleep disturbances and interleukin 6 receptor inhibition in rheumatoid arthritis. J Rheumatol 2012: 39: 60-2.
45. PEJOVIC S, BASTA M, VGONTZAS AN et al.: Effects of recovery sleep after one work week of mild sleep restriction on interleukin-6 and cortisol secretion and daytime sleepiness and performance. Am J Physiol Endocrinol Metab 2013: 305: E890-6.
46. KOJIMA M, KOJIMA T, ISHIGURO N et al.: Psychosocial factors, disease status, and quality of life in patients with rheumatoid arthritis. J Psychosom Res 2009: 67: 425-31.
47. GÅFVELS C, HäGERSTRöM M, NORDMARK B, WäNDELL PE: Psychosocial problems among newly diagnosed rheumatoid arthritis patients. Clin Rheumatol 2012: 31: 521-9.
48. van DARTEL SAA, REPPING-WUTS JWJ, van HOOGMOED D, BLEIJENBERG G, van RIEL PLCM, FRANSEN J: Association between fatigue and pain in rheumatoid arthritis: does pain precede fatigue or does fatigue precede pain? Arthritis Care Res (Hoboken) 2013: 65: 862-9.
49. EDINGER JD, FINS AI, GLENN DM et al.: Insomnia and the eye of the beholder: are there clinical markers of objective sleep disturbances among adults with and without insomnia complaints? J Consult Clin Psychol 2000: 68: 586-93.
50. MORIN CM, ESPIE CA: Insomnia: A Clinical Guide to Assessment and Treatment. Boston, MA: Springer Science + Business Media Inc, 2004.
51. POLLARD LC, CHOY EH, GONZALEZ J, KHOSHABA B, SCOTT DL: Fatigue in rheumatoid arthritis reflects pain, not disease activity. Rheumatology (Oxford) 2006: 45: 885-9.
52. STAUD R: Peripheral and central mechanisms of fatigue in inflammatory and noninflammatory rheumatic diseases. Curr Rheumatol Rep 2012: 14: 539-48.
53. LAGO R, GóMEZ R, LAGO F, GóMEZ-REINO J, GUALILLO O: Leptin beyond body weight regulation-current concepts concerning its role in immune function and inflammation. Cell Immunol 2008: 252: 139-45.
54. KOPEC-MEDREK M, KOTULSKA A, WIDUCHOWSKA M, ADAMCZAK M, WIECEK A, KUCHARZ EJ: Plasma leptin and neuropeptide Y concentrations in patients with rheumatoid arthritis treated with infliximab, a TNF-a antagonist. Rheumatol Int 2012: 32: 3383-9.
55. STRAUB RH, HäRLE P, ATZENI F, WEIDLER C, CUTOLO M, SARZI-PUTTINI P: Sex hormone concentrations in patients with rheumatoid arthritis are not normalized during 12 weeks of anti-tumor necrosis factor therapy. J Rheumatol 2005: 32: 1253-8.
56. TORRES-CHáVEZ KE, SANFINS JM, CLEMENTE-NAPIMOGA JT et al.: Effect of gonadal steroid hormones on formalin-induced temporomandibular joint inflammation. Eur J Pain 2012: 16: 204-16.
57. YAMAGUCHI A, NOZAWA K, FUJISHIRO M et al.: Estrogen inhibits apoptosis and promotes CC motif chemokine ligand 13 expression on synovial fibroblasts in rheumatoid arthritis. Immunopharmacol Immunotoxicol 2012: 34: 852-7.